Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenticlair 1 trial of inhaled BI 3720931 in cystic fibrosis
NL-OMON59478Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2025
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of BI 3720931 in cystic fibrosis (CF) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Drug-related treatment-emergent adverse events up to Week 24 and Absolute change from baseline in FEV1 percent predicted at Week 8. Started Jan 2025; status: completed.
02
Drugs
BI 3720931
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON59478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59478.